Geographical and temporal variations in clozapine prescription for schizophrenia

European Neuropsychopharmacology

Volumn 22, Issue 11, 2012, Pages 818-824

  Nielsen, Jimmi ^a   Røge, Rasmus ^a   Schjerning, Ole ^a   Sørensen, Holger J ^a   Taylor, David ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotic; Augmentation; Clozapine; Polypharmacy; Prescribing pattern; Schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; BIOGEOGRAPHIC REGION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DENMARK; DRUG PRESCRIPTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SCHIZOPHRENIA; SPATIO-TEMPORAL ANALYSIS; TIME-TO-TREATMENT;

EID: 84867514551     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.03.003     Document Type: Article

References (35)

1. Agid O., Arenovich T., Sajeev G., Zipursky R.B., Kapur S., Foussias G., Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J. Clin. Psychiatry 2011, 72:1439-1444.
2. Agid O., Remington G., Kapur S., Arenovich T., Zipursky R.B. Early use of clozapine for poorly responding first-episode psychosis. J. Clin. Psychopharmacol. 2007, 27:369-373.
3. Barnes T.R. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2011, 25:567-620.
4. Chong S.A., Remington G.J., Lee N., Mahendran R. Contrasting clozapine prescribing patterns in the east and west?. Ann. Acad. Med. Singapore 2000, 29:75-78.
5. Conley R.R., Kelly D.L., Lambert T.J., Love R.C. Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr. Serv. 2005, 56:320-323.
6. Conley R.R., Kelly D.L., Richardson C.M., Tamminga C.A., Carpenter W.T. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J. Clin. Psychopharmacol. 2003, 23:668-671.
7. Glazer W.M., Dickson R.A. Clozapine reduces violence and persistent aggression in schizophrenia. J. Clin. Psychiatry 1998, 59:8-14. Suppl. 3.
8. Hayhurst K.P., Brown P., Lewis S.W. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J. Psychopharmacol. 2002, 16:169-175.
9. Kelly D.L., Kreyenbuhl J., Dixon L., Love R.C., Medoff D., Conley R.R. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr. Bull. 2007, 33:1221-1224.
10. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
12. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
13. McKean A., Vella-Brincat J. Drug usage to alleviate the adverse effects of clozapine. Australas. Psychiatry 2011, 19:175.
14. McKean A., Vella-Brincat J., Begg E. Prescribing and monitoring clozapine in Christchurch. Australas. Psychiatry 2008, 16:263-267.
15. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60:82-91.
16. Meltzer H.Y., Lee M., Cola P. The evolution of treatment resistance: biologic implications. J. Clin. Psychopharmacol. 1998, 18:5S-11S.
17. Moore T.A., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., Essock S.M., Finnerty M., Marder S.R., Miller del D., McEvoy J.P., Robinson D.G., Schooler N.R., Shon S.P., Stroup T.S., Miller A.L. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J. Clin. Psychiatry 2007, 68:1751-1762.
18. Mors O., Perto G.P., Mortensen P.B. The Danish Psychiatric Central Research Register. Scand. J. Public Health 2011, 39:54-57.
19. Nielsen J., Dahm M., Lublin H., Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J. Psychopharmacol. 2010, 24:965-971.
20. Nielsen J., Damkier P., Lublin H., Taylor D. Optimizing clozapine treatment. Acta Psychiatr. Scand. 2011, 123:411-422.
21. Nielsen J., Foldager L., Meyer J.M. Increased use of antibiotics in patients treated with clozapine. Eur. Neuropsychopharmacol. 2009, 19:483-486.
22. Nielsen J., Graff C., Kanters J.K., Toft E., Taylor D., Meyer J.M. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011, 25:473-490.
23. Nielsen J., le Quach P., Emborg C., Foldager L., Correll C.U. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr. Scand. 2010, 122:356-366.
24. Nielsen J., Meyer J.M. Risk factors for Ileus in patients with schizophrenia. Schizophr. Bull 2010.
25. Nielsen J., Skadhede S., Correll C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010, 35:1997-2004.
26. Nooijen P.M., Carvalho F., Flanagan R.J. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum. Psychopharmacol. 2011, 26:112-119.
27. Pantelis C., Lambert T.J. Managing patients with "treatment-resistant" schizophrenia. Med. J. Aust. 2003, 178:S62-S66.
28. Peacock L., Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J. Clin. Psychiatry 1994, 55:44-49.
29. Roy M.A., Merette C., Maziade M. Subtyping schizophrenia according to outcome or severity: a search for homogeneous subgroups. Schizophr. Bull. 2001, 27:115-138.
30. Sernyak M.J., Rosenheck R.A. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr. Serv. 2008, 59:567-569.
31. Tan C.H., Shinfuku N., Sim K. Psychotropic prescription practices in east Asia: looking back and peering ahead. Curr. Opin. Psychiatry 2008, 21:645-650.
32. Taylor D., Olofinjana O., Rahimi T. Use of antacid medication in patients receiving clozapine: a comparison with other second-generation antipsychotics. J. Clin. Psychopharmacol. 2010, 30:460-461.
33. Taylor D.M., Smith L., Gee S.H., Nielsen J. Augmentation of clozapine with a second antipsychotic-a meta-analysis. Acta Psychiatr. Scand. 2012, 125:15-24.
34. Taylor D.M., Young C., Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J. Clin. Psychiatry 2003, 64:30-34.
35. WHO, 2012. World Health Organization, Collaborating Centre Drug Statistics Methodology.